Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $43.00.

Several analysts have recently commented on BCAX shares. Cantor Fitzgerald started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating on the stock. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright initiated coverage on Bicara Therapeutics in a research report on Friday, December 6th. They issued a “buy” rating and a $42.00 price objective on the stock. TD Cowen began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th.

Institutional Trading of Bicara Therapeutics

Large investors have recently made changes to their positions in the company. Cinctive Capital Management LP acquired a new position in Bicara Therapeutics in the third quarter valued at about $229,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $255,000. Jane Street Group LLC bought a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $309,000. Teachers Retirement System of The State of Kentucky bought a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $358,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $462,000.

Bicara Therapeutics Stock Up 2.0 %

Shares of Bicara Therapeutics stock opened at $19.12 on Thursday. Bicara Therapeutics has a 12-month low of $16.01 and a 12-month high of $28.09. The stock’s 50-day moving average price is $20.77.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.